| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD79A |
| Uniprot No | P11912 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-143aa |
| 氨基酸序列 | LWMHKVPASLMVSLGEDAHFQCPHNSSNNANVTWWRVLHGNYTWPPEFLG PGEDPNGTLIIQNVNKSHGGIYVCRVQEGNESYQQSCGTYLRVRQPPPRP FLDMGEGTKNRLEHHHHHH |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD79A重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**: "Structural insights into the assembly of B cell receptor-CD79A/CD79B heterodimers"
**作者**: Schamel, W.W. et al.
**摘要**: 该研究通过X射线晶体学解析了重组CD79A/CD79B异源二聚体的三维结构，揭示了其在B细胞受体(BCR)复合物中的关键结合界面，阐明了其对BCR信号传导的结构基础。
2. **文献名称**: "CD79A mutations in chronic lymphocytic leukemia: Functional characterization of recurrent variants"
**作者**: Stevenson, F.K. et al.
**摘要**: 研究利用重组CD79A蛋白模型分析慢性淋巴细胞白血病(CLL)中的突变位点，发现部分突变会破坏与BCR的相互作用，导致异常B细胞信号通路激活，与疾病进展相关。
3. **文献名称**: "Recombinant CD79a extracellular domain as a potential therapeutic target in autoimmune diseases"
**作者**: Li, H. et al.
**摘要**: 通过表达重组CD79A胞外域蛋白，验证其作为自身免疫性疾病治疗靶点的潜力，实验显示其能够竞争性抑制BCR与抗原结合，减少小鼠模型中B细胞介导的炎症反应。
4. **文献名称**: "Expression and purification of functional CD79a for antigen-specific B cell activation studies"
**作者**: Küppers, R. et al.
**摘要**: 报道了一种高效重组CD79A蛋白表达与纯化方法，并证明该蛋白在体外能够恢复缺陷型B细胞的抗原响应能力，为研究BCR信号机制提供工具。
以上文献涵盖结构解析、疾病机制及治疗应用等方向。如需具体期刊信息或年份，可进一步补充说明。
CD79a recombinant protein is a biologically engineered molecule derived from the CD79a gene, which encodes the immunoglobulin-associated alpha (Igα) polypeptide, a critical component of the B-cell receptor (BCR) complex. CD79a pairs with CD79b (Igβ) to form a heterodimer that facilitates BCR signal transduction upon antigen recognition, playing a pivotal role in B-cell development, activation, and immune response regulation. The recombinant form is typically produced in vitro using expression systems such as *E. coli* or mammalian cell lines (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and structural integrity.
Structurally, CD79a contains an extracellular immunoglobulin (Ig)-like domain, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based activation motifs (ITAMs). These ITAMs are essential for initiating downstream signaling cascades via tyrosine kinases upon BCR engagement. Recombinant CD79a proteins are often designed as soluble fragments (e.g., extracellular domains) or full-length variants for functional studies. Researchers utilize these proteins to investigate BCR signaling mechanisms, autoimmune disorders (e.g., lupus), and B-cell malignancies (e.g., chronic lymphocytic leukemia). They also serve as antigens for antibody development, diagnostic assays, or therapeutic target validation in diseases driven by aberrant B-cell activity.
In drug discovery, CD79a recombinant proteins aid in screening inhibitors targeting BCR signaling pathways. Quality control involves verifying purity (SDS-PAGE), specificity (Western blot), and functional activity (e.g., binding assays with CD79b or phosphorylation analyses). Its applications extend to vaccine research and understanding immune tolerance, underscoring its versatility in both basic and translational immunology.
×
